Gilbert P - Search Results

1

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).

Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN; Step/HVTN 504 Study Team. Duerr A, et al. Among authors: gilbert p. J Infect Dis. 2012 Jul 15;206(2):258-66. doi: 10.1093/infdis/jis342. Epub 2012 May 4. J Infect Dis. 2012. PMID: 22561365 Free PMC article. Clinical Trial.

2

Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.

Gilbert PB, Self SG, Ashby MA. Gilbert PB, et al. Biometrics. 1998 Sep;54(3):799-814. Biometrics. 1998. PMID: 9750238

3

Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation.

Gilbert P, Self S, Rao M, Naficy A, Clemens J. Gilbert P, et al. J Clin Epidemiol. 2001 Jan;54(1):68-85. doi: 10.1016/s0895-4356(00)00258-4. J Clin Epidemiol. 2001. PMID: 11165470 Review.

4

Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal.

Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S, Kanki PJ. Gilbert PB, et al. Stat Med. 2003 Feb 28;22(4):573-93. doi: 10.1002/sim.1342. Stat Med. 2003. PMID: 12590415

5

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE; NIAID HIV Vaccine Trials Network. Gilbert PB, et al. Vaccine. 2003 Jun 20;21(21-22):2933-47. doi: 10.1016/s0264-410x(03)00158-0. Vaccine. 2003. PMID: 12798637 Clinical Trial.

6

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.

Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. Gilbert PB, et al. J Infect Dis. 2003 Jul 15;188(2):179-93. doi: 10.1086/376449. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854072

7

Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

Gilbert PB, Bosch RJ, Hudgens MG. Gilbert PB, et al. Biometrics. 2003 Sep;59(3):531-41. doi: 10.1111/1541-0420.00063. Biometrics. 2003. PMID: 14601754

8

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

Lee D, Graham BS, Chiu YL, Gilbert PB, McElrath MJ, Belshe RB, Buchbinder SP, Sheppard HW, Koblin BA, Mayer KH, Keefer MC, Mulligan MJ, Celum CL. Lee D, et al. Among authors: gilbert pb. J Infect Dis. 2004 Sep 1;190(5):903-7. doi: 10.1086/423284. Epub 2004 Jul 29. J Infect Dis. 2004. PMID: 15295694 Clinical Trial.

9

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial.

Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, Heyward WL, Jobes DV, Popovic V, Self SG, Sinangil F, Burke D, Berman PW. Gilbert PB, et al. J Infect Dis. 2005 Mar 1;191(5):666-77. doi: 10.1086/428405. Epub 2005 Jan 27. J Infect Dis. 2005. PMID: 15688279 Clinical Trial.

10

Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation.

Gilbert PB, Sun Y. Gilbert PB, et al. Biostatistics. 2005 Jul;6(3):374-94. doi: 10.1093/biostatistics/kxi014. Epub 2005 Apr 14. Biostatistics. 2005. PMID: 15831584

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,410 results

Search Page

Filters